Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Background: Cancer patients are at high risk of psychological problems and COVID-19 infection, which makes them even more vulnerable to mood disorders. Our objectives were to analyze the level of anxiety and depression among patients with advanced cancer during the COVID-19 pandemic and to analyze the association between sociodemographic, clinical, and psychological factors in patients with advanced cancer.

Methods: A prospective, cross-sectional, multicenter study was conducted in 15 oncology departments in Spain. Patients with locally advanced unresectable or metastatic cancer who were candidates for systemic treatment were included. Participants completed demographic information and the Brief Symptom Inventory (BSI), sociodemographic, clinical, and psychological factors in patients with advanced cancer. The aim of this study is to investigate the relationship between cancer patients. The results highlight the significant impact of Demoralization on anxiety (p < 0.001, R² = 0.076). Unmarried patients presented higher rates of depression (p = 0.043) and positively correlated with time since diagnosis (p = 0.076). Unmarried patients presented higher rates of depression (p = 0.043) and positively correlated with time since diagnosis (p = 0.076).

Results: A total of 374 patients were recruited (April 2020-2021). The mean age was 64.2 years (34-88) and 48.7% were women. The most frequent were lung (30.7%) and colon (14.2%) cancers and most had metastases (78.6%). The most frequent therapy was chemotherapy (57.9%). The prevalence of anxiety and depression was 35% and 34%, respectively. Anxiety and depression levels were higher in women (p < 0.001 and p < 0.003, respectively). Patients <65 years (p = 0.017) and with an oncologist-estimated survival of >18 months (p = 0.033) had more anxiety symptoms. Logistic regression analysis revealed that women, patients with coping based on anxious preoccupation and hopelessness had higher risk of anxiety and depression (all, p < 0.001).

Conclusions: Patients with advanced cancer who start treatment during the COVID-19 pandemic experience high levels of depression and anxiety. Early diagnosis and the development of intervention strategies are needed especially in specific patient subgroups such as women with long survived estimated times.

Legal entity responsible for the study: The authors.

Funding: This work was funded by FSEOM (Spanish Society of Medical Oncology Foundation).

Disclosure: B. Obispo: Financial Interests, Personal, Invited Speaker: Lilly; Financial Interests, Personal, Invited Speaker: Sanofi; Financial Interests, Personal, Invited Speaker: Fresenius; Financial Interests, Personal, Invited Speaker: Roel. R. Hernandez: Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Invited Speaker: Lilly; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Merck; Financial Interests, Personal, Invited Speaker: Ipsen. P. Cruz: Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Invited Speaker: Bristol; Financial Interests, Personal, Advisory Board: Boehringer Ingelheim. A. Fernandez Montes: Financial Interests, Personal, Advisory Role: MSD; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Invited Speaker: Servier; Financial Interests, Personal, Invited Speaker: Lilly; Financial Interests, Personal, Advisory Role: Lilly; Financial Interests, Personal, Advisory Role: MSD; Financial Interests, Personal, Invited Speaker: Lilly; Financial Interests, Personal, Advisory Role: MSD; Financial Interests, Personal, Invited Speaker: Lilly; Financial Interests, Personal, Advisory Role: MSD; Financial Interests, Personal, Invited Speaker: Lilly; Financial Interests, Personal, Advisory Role: MSD; Financial Interests, Personal, Invited Speaker: Lilly; Financial Interests, Personal, Advisory Role: MSD; Financial Interests, Personal, Invited Speaker: Lilly; Financial Interests, Personal, Advisory Role: MSD; Financial Interests, Personal, Invited Speaker: Lilly; Financial Interests, Personal, Advisory Role: MSD; Financial Interests, Personal, Invited Speaker: Lilly.